Corcept Therapeutics (CORT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Corcept Therapeutics Announces Second Quarter 2015 Results and Provides Corporate Update
August 5, 2015 4:06 PM EDTMENLO PARK, CA -- (Marketwired) -- 08/05/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT)
Per-share net loss in the second quarter narrows to $0.02, from $0.07 in the same period last year Excluding non-cash expenses, non-GAAP net income for the second quarter is $369,000, compared to a non-GAAP net loss of $5.4 million in the second quarter of 2014 Second quarter revenue is $12.0 million, compared to $5.9 million in the second quarter of 2014, a 104 percent increase 2015 revenue guidance is revised to $49 - $53 million Patient dosing continues in the efficacy portion of the company's Phase 1/2 trial... More